Immunostaining and Western blot with the anti-p44/WDR77 antibody revealed that p44/WDR77 is cytoplasmic in AR-positive prostate cancer LNCaP (Figure 2A, top panels) and 22RV1 cells, in agreement with our previously reported data [2]. This evidence concerns the gene WDR77 and prostate carcinoma.